BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.730
+0.050 (2.98%)
At close: Apr 17, 2026, 4:00 PM EDT
1.690
-0.040 (-2.31%)
After-hours: Apr 17, 2026, 4:10 PM EDT
BeyondSpring Employees
BeyondSpring had 44 employees as of December 31, 2025. The number of employees increased by 4 or 10.00% compared to the previous year.
Employees
44
Change (1Y)
4
Growth (1Y)
10.00%
Revenue / Employee
n/a
Profits / Employee
-$22,864
Market Cap
71.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 44 | 4 | 10.00% |
| Dec 31, 2024 | 40 | 4 | 11.11% |
| Dec 31, 2023 | 36 | -37 | -50.68% |
| Dec 31, 2022 | 73 | -30 | -29.13% |
| Dec 31, 2021 | 103 | 12 | 13.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| PMV Pharmaceuticals | 54 |
| PDS Biotechnology | 24 |
| MiNK Therapeutics | 23 |
| iBio, Inc. | 20 |
| Grace Therapeutics | 6 |
BYSI News
- 25 days ago - BeyondSpring Files 2025 Annual Report on Form 10-K - GlobeNewsWire
- 2 months ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 4 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 10 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 11 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 1 year ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire